With about 1.4 million deaths per year, viral hepatitis are a leading cause of deaths globally, mainly from end-stage liver disease i.e cirrhosis and liver cancer. This number of deaths is now higher than the number of deaths due to malaria, tuberculosis or HIV. Most of these deaths occur in resource-limited countries especially in Africa. The World Health Organisation (WHO) has called for elimination of Hepatitis B and C viruses by 2030.
Africa is one of the most endemic areas in the world for viral hepatitis but interventions to prevent, screen and treat viral hepatitis are very limited accross the continent especially in sub-Saharan Africa.
The PROLIFICA programme is a unique research platform built on a strong epidemiological, clinical and scientific collaboration in order to fill research and intervention gaps on viral hepatitis in Africa.